secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-10-19T20:10:28+00:00
Accession:  0001778922-26-000052
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

SpyGlass reports 4-year BIM-IOL data: 37% IOP cut, 86% off drops, no product-related AEs
--------------------------------------------------------------------------------

- Interim 4-year data in 21 evaluable patients: mean IOP fell 37% to 15.9 mmHg from 25.1 mmHg post-washout across 75/150/300 mcg dose groups.
- 86% (18 of 21) remained off all topical IOP-lowering drops; 90% maintained ≥20/25 best corrected distance visual acuity.
- No product-related adverse events reported; FIH trial enrolled 23 patients, with 21 evaluable at 48 months (one moved abroad, one discontinued after cancer diagnosis).
- BIM-IOL System is designed to deliver bimatoprost for up to 7 years in the FIH trial; Phase 3 version targets 3 years, with a 505(b)(2) NDA planned.
- CEO Patrick Mooney cites approximately 1 million U.S. cataract procedures annually in glaucoma patients as the unmet need being targeted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/0001778922-26-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm
  HTML page:      https://secwatch.observer/filing/0001778922-26-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer